Venture firm Medicxi is investing $11.2m in Kymo Therapeutics, a startup launched by biotech company Metabrain Research to advance its kynurenine metabolism inhibitor research.
France-headquartered biotechnology company Metabrain Research has formed a UK-based startup called Kymo Therapeutics with up to €10m ($11.2m) of funding from venture capital firm Medicxi to extend its kynurenine metabolism research.
The body’s kynurenine pathway leads to the production of a coenzyme known as nicotinamide adenine dinucleotide. It is ordinarily well balanced but when inflamed can lead to diseases such as diabetes, neurodegenerative disorders, depression and cancer.
Kymo is aiming to develop a drug that will inhibit the kynurenine metabolism…
